/ /

  • linkedin
  • Increase Font
  • Sharebar

    Sustained drug delivery moving toward clinical use


    Clearside Biomedical

    Clearside aims to exploit one of the largest yet most contained channels in the eye, the suprachoroidal space. If current clinical programs support successful animal studies, the company will transform the choroid into a drug target and the suprachoroidal space into a reliable delivery channel.

    “You can put a large amount of drug into the suprachoroidal space and it spreads very evenly across the posterior of the eye,” said Daniel White, president and CEO.

    Injection into the suprachoroidal space compartmentalizes drug in the choroid and the retina with minimal diffusion into other ocular tissues. Suprachoroidal delivery produces similar therapeutic results as intravitreal injection, while using just 10% of the drug concentration typically injected.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results